Analysts Expect Editas Medicine Inc (NASDAQ:EDIT) Will Post Earnings of -$0.59 Per Share

Wall Street analysts expect that Editas Medicine Inc (NASDAQ:EDIT) will post earnings per share of ($0.59) for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Editas Medicine’s earnings. The highest EPS estimate is ($0.41) and the lowest is ($0.80). Editas Medicine posted earnings per share of ($0.82) in the same quarter last year, which indicates a positive year over year growth rate of 28%. The company is scheduled to report its next quarterly earnings report on Monday, August 5th.

On average, analysts expect that Editas Medicine will report full-year earnings of ($2.52) per share for the current fiscal year, with EPS estimates ranging from ($3.13) to ($1.88). For the next financial year, analysts expect that the firm will report earnings of ($2.87) per share, with EPS estimates ranging from ($3.15) to ($2.68). Zacks Investment Research’s earnings per share averages are an average based on a survey of research analysts that follow Editas Medicine.

Editas Medicine (NASDAQ:EDIT) last announced its earnings results on Tuesday, May 7th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.03). Editas Medicine had a negative net margin of 359.93% and a negative return on equity of 47.64%. The company had revenue of $2.07 million for the quarter, compared to the consensus estimate of $7.62 million. During the same quarter in the previous year, the firm earned ($0.67) earnings per share. The company’s revenue for the quarter was down 47.3% compared to the same quarter last year.

Several equities research analysts have issued reports on the stock. BidaskClub upgraded shares of Editas Medicine from a “hold” rating to a “buy” rating in a research report on Thursday, April 25th. Evercore ISI began coverage on shares of Editas Medicine in a research report on Thursday, April 11th. They set an “outperform” rating for the company. Oppenheimer restated a “hold” rating on shares of Editas Medicine in a report on Wednesday, May 8th. Zacks Investment Research lowered shares of Editas Medicine from a “buy” rating to a “hold” rating in a report on Friday, May 10th. Finally, ValuEngine upgraded shares of Editas Medicine from a “sell” rating to a “hold” rating in a report on Friday, March 1st. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and six have given a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $37.80.

Large investors have recently bought and sold shares of the stock. Creative Planning raised its holdings in Editas Medicine by 7.6% during the 1st quarter. Creative Planning now owns 26,504 shares of the company’s stock valued at $648,000 after buying an additional 1,879 shares during the last quarter. Capital Impact Advisors LLC raised its holdings in Editas Medicine by 10.9% during the 4th quarter. Capital Impact Advisors LLC now owns 63,637 shares of the company’s stock valued at $1,319,000 after buying an additional 6,231 shares during the last quarter. 361 Capital LLC bought a new stake in Editas Medicine during the 4th quarter valued at $2,097,000. Squarepoint Ops LLC raised its holdings in Editas Medicine by 49.8% during the 4th quarter. Squarepoint Ops LLC now owns 84,319 shares of the company’s stock valued at $1,918,000 after buying an additional 28,019 shares during the last quarter. Finally, FDx Advisors Inc. bought a new stake in Editas Medicine during the 4th quarter valued at $241,000. Institutional investors own 75.43% of the company’s stock.

Editas Medicine stock traded down $0.53 during mid-day trading on Friday, hitting $21.88. 857 shares of the company traded hands, compared to its average volume of 640,369. Editas Medicine has a one year low of $17.80 and a one year high of $41.43. The firm has a market cap of $1.10 billion, a PE ratio of -9.44 and a beta of 2.47. The company has a debt-to-equity ratio of 0.07, a current ratio of 8.46 and a quick ratio of 8.46.

Editas Medicine Company Profile

Editas Medicine, Inc operates as a clinical stage genome editing company. The company focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas.

See Also: Consumer Price Index (CPI)

Get a free copy of the Zacks research report on Editas Medicine (EDIT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Editas Medicine (NASDAQ:EDIT)

Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.